With the expanded approval, Novartis' drug entered the IgA nephropathy (IgAN) market and will compete with Swedish drugmaker Calliditas' Tarpeyo and Travere Therapeutics' Filspari.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/CQmyVT2
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment